![]() |
|
|
Vol. 280, Issue 2, 820-828, 1997
Research Service, Department of Veterans Affairs Medical Center and
Department of Behavioral Neuroscience, Oregon Health Sciences
University, Portland, Oregon
Recent work found that lower endogenous levels of the
-aminobutyric
acid-agonist, neuroactive steroid 3
-hydroxy-5
-pregnan-20-one (3
,5
-THP) may be correlated with increased ethanol withdrawal severity in the selectively bred Withdrawal Seizure-Prone and -Resistant mice. The present studies were conducted to determine whether decreased sensitivity to 3
,5
-THP was correlated with ethanol withdrawal hyperexcitability in another genetic mouse model,
namely the C57BL/6 (B6) and DBA/2 (D2) inbred strains. These strains
also differ in ethanol withdrawal severity (D2
B6). B6 and D2
male mice were injected with 3
,5
-THP (0-10 mg/kg i.p.) 15 min
before the timed tail vein infusion of pentylenetetrazol. B6 mice were
more sensitive than D2 animals to the anticonvulsant effect of
3
,5
-THP. Subsequent studies measured sensitivity to several of
the pharmacological effects of 3
,5
-THP. B6 and D2 male mice were
injected with 3
,5
-THP (0-32 mg/kg) before testing for locomotor
activation (total number of entries) and anxiolysis (percent open arm
entries) on the elevated plus maze, muscle relaxation (impairment of
forelimb grip strength), ataxia (impairment of Rotarod performance) and
seizure susceptibility to pentylenetetrazol. B6 mice were more
sensitive than D2 animals to the anxiolytic, locomotor stimulant and
anticonvulsant effects of 3
,5
-THP. In contrast, D2 mice were more
sensitive than B6 mice to 3
,5
-THP-induced muscle relaxation and
ataxia. Plasma 3
,5
-THP levels did not differ in the B6 and D2
mice injected with this steroid, suggesting that the strain differences
were not pharmacokinetic. Collectively, the results in selectively bred
Withdrawal Seizure-Prone and -Resistant mice and B6 and D2 inbred
strains suggest that genetic differences in neuroactive steroid
sensitivity and biosynthesis may contribute to ethanol withdrawal
severity.
This article has been cited by other articles:
![]() |
F. E. Lotrich, R. R. Bies, G. S. Smith, and B. G. Pollock Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol, July 1, 2006; 20(4 Suppl): 33 - 40. [Abstract] [PDF] |
||||
![]() |
E. E. Shannon, P. Porcu, R. H. Purdy, and K. A. Grant Characterization of the Discriminative Stimulus Effects of the Neuroactive Steroid Pregnanolone in DBA/2J and C57BL/6J Inbred Mice J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 675 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Finn, E. J. Gallaher, and J. C. Crabbe Differential Change in Neuroactive Steroid Sensitivity during Ethanol Withdrawal J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 394 - 405. [Abstract] [Full Text] |
||||
![]() |
A. G. Herzog Psychoneuroendocrine Aspects of Temporolimbic Epilepsy: Part I. Brain, Reproductive Steroids, and Emotions Psychosomatics, April 1, 1999; 40(2): 95 - 101. [Abstract] [Full Text] |
||||